期刊
NEUROLOGICAL SCIENCES
卷 43, 期 2, 页码 1273-1280出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-021-05426-5
关键词
Anti-CGRP; Calcitonin gene-related peptide; OnabotulinumtoxinA; Migraine treatment; Prophylaxis
The study found that erenumab significantly reduced migraine frequency and pain medication intake in refractory chronic migraine patients with medication overuse headache. After 3 months, 51% of patients experienced a reduction of at least 50% in monthly headache days, with 20% experiencing a reduction of at least 75%. Allodynia was identified as a negative predictive factor for erenumab response, while 64% of patients clinically converted to episodic migraine without medication overuse.
Objective To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. Methods In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. Study inclusion was limited to patients who previously failed onabotulinumtoxinA in addition to at least three other pharmacological commonly used migraine preventive medication classes. Results Of 396 patients who received erenumab, 38% (n = 149) met inclusion criteria. After 3 months, 51% (n = 76) and 20% (n = 30) patients achieved >= 50% and >= 75% reduction in monthly headache days, respectively. Monthly pain medications intake decreased from 46.1 +/- 35.3 to 16.8 +/- 13.9 (p < 0.001), while monthly headache days decreased from 25.4 +/- 5.4 to 14.1 +/- 8.6 (p < 0.001). Increasing efficacy of erenumab over the study period was observed. Allodynia was a negative predictive factor of erenumab response (odds ratio = 0.47; p = 0.03). Clinical conversion to episodic migraine with no medication overuse was observed in 64% (n = 96) patients. No serious adverse events were observed. Conclusions Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据